Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label, Dose Escalation Study to Evaluate the Safety and Efficacy of Intralesional Injection of STP705 in Adult Subjects With Facial Cutaneous Squamous Cell Carcinoma in Situ (isSCC)

Next Previous
Trial Profile

An Open Label, Dose Escalation Study to Evaluate the Safety and Efficacy of Intralesional Injection of STP705 in Adult Subjects With Facial Cutaneous Squamous Cell Carcinoma in Situ (isSCC)

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 20 Mar 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs STP 705 (Primary)
  • Indications Skin cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Sponsors Sirnaomics

Most Recent Events

  • 15 Mar 2024 Status changed from active, no longer recruiting to completed.
  • 28 Feb 2023 Planned End Date changed from 1 Feb 2023 to 1 Jul 2023.
  • 28 Feb 2023 Planned primary completion date changed from 1 Dec 2022 to 1 Jul 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top